Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH – Get Free Report) (TSE:AUP) was the target of a significant drop in short interest during the month of July. As of July 15th, there was short interest totalling 8,700,000 shares, a drop of 15.7% from the June 30th total of 10,320,000 shares. Based on an average daily trading volume, of 1,280,000 shares, the short-interest ratio is currently 6.8 days.
Analysts Set New Price Targets
Separately, StockNews.com raised shares of Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, May 3rd. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $10.00.
Get Our Latest Report on Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Stock Performance
Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Free Report) (TSE:AUP) last posted its earnings results on Thursday, May 2nd. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.14. The company had revenue of $50.30 million during the quarter, compared to the consensus estimate of $46.30 million. Aurinia Pharmaceuticals had a negative net margin of 32.69% and a negative return on equity of 15.06%. Equities research analysts predict that Aurinia Pharmaceuticals will post 0.15 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in AUPH. Vermillion & White Wealth Management Group LLC purchased a new position in Aurinia Pharmaceuticals in the fourth quarter valued at $30,000. Tidemark LLC purchased a new position in Aurinia Pharmaceuticals in the fourth quarter valued at $39,000. Virtu Financial LLC purchased a new position in Aurinia Pharmaceuticals in the first quarter valued at $78,000. Eagle Asset Management Inc. purchased a new position in Aurinia Pharmaceuticals in the fourth quarter valued at $92,000. Finally, China Universal Asset Management Co. Ltd. increased its holdings in Aurinia Pharmaceuticals by 67.4% in the first quarter. China Universal Asset Management Co. Ltd. now owns 27,802 shares of the biotechnology company’s stock valued at $139,000 after buying an additional 11,189 shares in the last quarter. 36.83% of the stock is currently owned by institutional investors and hedge funds.
Aurinia Pharmaceuticals Company Profile
Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.
Recommended Stories
- Five stocks we like better than Aurinia Pharmaceuticals
- Following Congress Stock Trades
- AbbVie Analysts Lead the Stock Higher as Humira Worries Recede
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Harley-Davidson Stock Revs Up With Billion Dollar Buyback Program
- How to Use Stock Screeners to Find Stocks
- Cruise Line Stock Sinks Despite Beating EPS and Raised Guidance
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.